» Articles » PMID: 29134489

The Quick Loss of Carbapenem Susceptibility in Pseudomonas Aeruginosa at Intensive Care Units

Overview
Publisher Springer
Specialties Pharmacology
Pharmacy
Date 2017 Nov 15
PMID 29134489
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background Patients colonized with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) strains upon admission to the intensive care unit (ICU) tend to be quickly followed by detected carbapenem-resistant P. aeruginosa strains after admission. Objective To assess the risk factors associated with the quick loss of carbapenem susceptibility and to identify time threshold of prior antimicrobial exposure for the loss during ICU stay. Setting A tertiary-care teaching hospital with 2560 beds located in the northwest region of China. Method A retrospective observational study was conducted between January 2013 and April 2016 at ICUs. Logistic regression analysis was used to assess risk factors, and receiver operating characteristic (ROC) analyses were constructed to identify the time threshold. Main outcome measure The time threshold and risk factors for the quick loss of carbapenem susceptibility. Results Among the 84 patients with CSPA initially, 32 (38.1%) patients were observed to have a loss of carbapenem susceptibility during ICU stay. Logistic regression analyses showed that previous carbapenem exposure was only independently associated with the loss of carbapenem susceptibility (odds ratio 13.16; 95% CI 3.13-55.24; p < 0.001). The optimal cut-off was 3.5 days on ROC curve, indicating the high risk for loss of susceptibility. Conclusion In order to alleviate selective pressure caused by antipseudomonal carbapenems exposure, continued research is needed to determine the most appropriate carbapenems treatment strategies.

Citing Articles

The prognostic value of neutrophil-to-lymphocyte ratio in adult carbapenem-resistant infection: a retrospective cohort study.

Wang Z, Li R, Yuan Z, Zhang Z, Qian K Front Cell Infect Microbiol. 2024; 14:1461325.

PMID: 39669277 PMC: 11634867. DOI: 10.3389/fcimb.2024.1461325.


Risk factors and outcome associated with coinfection with carbapenem-resistant and carbapenem-resistant or a descriptive analysis.

Sophonsri A, Kelsom C, Lou M, Nieberg P, Wong-Beringer A Front Cell Infect Microbiol. 2023; 13:1231740.

PMID: 37908764 PMC: 10613969. DOI: 10.3389/fcimb.2023.1231740.


Carbapenem Resistant Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes.

Qin J, Zou C, Tao J, Wei T, Yan L, Zhang Y Infect Drug Resist. 2022; 15:2301-2314.

PMID: 35517901 PMC: 9064054. DOI: 10.2147/IDR.S358778.


Evaluation of carbapenem use in a tertiary hospital: antimicrobial stewardship urgently needed.

Zhang D, Cui K, Lu W, Bai H, Zhai Y, Hu S Antimicrob Resist Infect Control. 2019; 8:5.

PMID: 30627429 PMC: 6322243. DOI: 10.1186/s13756-018-0449-3.

References
1.
Ong D, Jongerden I, Buiting A, Leverstein-van Hall M, Speelberg B, Kesecioglu J . Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med. 2011; 39(11):2458-63. DOI: 10.1097/CCM.0b013e318225756d. View

2.
Hong D, Bae I, Jang I, Jeong S, Kang H, Lee K . Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa. Infect Chemother. 2015; 47(2):81-97. PMC: 4495280. DOI: 10.3947/ic.2015.47.2.81. View

3.
Harris A, Johnson J, Thom K, Morgan D, McGregor J, Ajao A . Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting. Infect Control Hosp Epidemiol. 2011; 32(7):719-22. PMC: 3312468. DOI: 10.1086/660763. View

4.
Goldstein E, Citron D, Peraino V, Elgourt T, Meibohm A, Lu S . Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53(12):5122-6. PMC: 2786360. DOI: 10.1128/AAC.00064-09. View

5.
Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay J, Bilocq F . In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents. 2010; 36(6):513-22. DOI: 10.1016/j.ijantimicag.2010.08.005. View